Entrepreneurs’ Organization Members Bolstered the Global Technology Enterprise Community at Web Summit
5.11.2021 13:00:00 EET | Business Wire | Press release
Entrepreneurs’ Organization (EO) supported technology entrepreneurs from around the world at the Web Summit conference. EO members donated their time to provide two masterclasses, two mentoring sessions and judged a live start-up pitching competition. Interested entrepreneurs were able to visit the EO booth to find more information on resources and programmes offered.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211105005353/en/
Entrepreneurs’ Organization Members Bolstered the Global Technology Enterprise Community at Web Summit (Photo: Business Wire)
Key EO contributions included:
- Mountaineer Saahil Mehta delivered a masterclass on how individuals can reinvent themselves to reach their own summits
- CEO Coach Eric Partaker delivered a masterclass on supercharging your productivity and achieving your full potential
- Private equity and venture capital investor Pavel Erochkine led mentoring hours for aspiring business leaders
- Author and marketer Nir Zavaro judged a start-up competition showcasing the world’s most promising early-stage start-ups
EO members leading the way in tech
More than 1,800 EO members – over 10% of its 15,000+ global membership – are in the technology industry globally. Of these, 170 are under 35.
EO supports the global tech entrepreneurship community by providing advice, mentorship and a support system to entrepreneurs in over 60 countries. Technology has played a crucial role in the survival and success of entrepreneurs around the world, and the opportunities it unlocked have supported businesses and led to growth and achievements for many business leaders in the last few years. Tech entrepreneurs have proven to be growth-oriented even during a global pandemic and have demonstrated the potential of technology for success.
EO at Web Summit
A delegation of nine EO members attended the summit, which took place at the Altice Arena & Fil in Lisbon from Monday 1 November until Thursday 4 November. They talked about their own experiences, the future of business and the lessons learned from the pandemic.
Experts from every industry came together for Web Summit to share ideas, network and discover the latest trends and opportunities. With a range of educational content, informative masterclasses and innovative roundtables, attendees gained valuable knowledge that will help them upskill and grow.
- ENDS –
Notes to editors
The Entrepreneurs’ Organization (EO) is a high-quality support network of 15,000+ like-minded leaders across 61 countries. EO helps entrepreneurs achieve their full potential through the power of life-enhancing connections, shared experiences, and collaborative learning. EO has been helping entrepreneurs achieve transformational growth since 1987 and its member network is committed to learning and helping each other succeed.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211105005353/en/
Contact information
For more information
Kathryn Cyr
Hanover Communications
kcyr@hanovercomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom